No label defined (Q28082855)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	No label defined	scientific article

Statements

scholarly article

1 reference

1 reference

Europe PubMed Central

Smoldering multiple myeloma (English)

1 reference

S. Vincent Rajkumar

1

object named as

S. V. Rajkumar

1 reference

author name string

O. Landgren

2

1 reference

M.-V. Mateos

3

1 reference

language of work or name

1 reference

publication date

14 May 2015

1 reference

1 reference

125

1 reference

20

1 reference

3069-75

1 reference

Smoldering multiple myeloma requiring treatment: time for a new definition?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

20 March 2017

Prevention of progression in monoclonal gammopathy of undetermined significance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

20 March 2017

Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

20 March 2017

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

20 March 2017

Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

20 March 2017

Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

29 September 2017

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

29 September 2017

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

29 September 2017

Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

29 September 2017

Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

29 September 2017

Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

29 September 2017

New approaches to smoldering myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

29 September 2017

Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

29 September 2017

Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

29 September 2017

High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

29 September 2017

A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

29 September 2017

The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

29 September 2017

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

29 September 2017

Multiple Myeloma Precursor Disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

29 September 2017

Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

29 September 2017

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

29 September 2017

Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

29 September 2017

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

29 September 2017

A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

29 September 2017

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

29 September 2017

New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

29 September 2017

Prevalence of monoclonal gammopathy of undetermined significance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

29 September 2017

Serum test for assessment of patients with Bence Jones myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

29 September 2017

Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

29 September 2017

Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

29 September 2017

A prognostic index for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

29 September 2017

Plasma cell labeling index in the evaluation of smoldering (asymptomatic) multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

2 June 2018

Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

2 June 2018

The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

27 November 2018

Treatment for high-risk smoldering myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

27 November 2018

Treatment for high-risk smoldering myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

27 November 2018

Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

27 November 2018

Haematological cancer: Treatment of smoldering multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

27 November 2018

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

27 November 2018

Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

27 November 2018

Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

27 November 2018

Redefining myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

27 November 2018

Diagnosis of Smoldering Multiple Myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

27 November 2018

Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

27 November 2018

Multiple Myeloma Precursor Disease: Current Clinical Dilemma and Future Opportunities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

27 November 2018

Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

27 November 2018

Thalidomide as initial therapy for early-stage myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

27 November 2018

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4432003

27 November 2018

Preventive strategies in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25838344

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden

1 reference

https://pubmed.ncbi.nlm.nih.gov/25838344

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Smoldering multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25838344

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple Myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25838344

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Smoldering multiple myeloma: natural history and recognition of an evolving type

1 reference

https://pubmed.ncbi.nlm.nih.gov/25838344

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25838344

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25838344

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25838344

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment for High-Risk Smoldering Myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25838344

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/25838344

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25838344

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2014-09-568899

1 reference

https://api.fatcat.wiki/v0/release/uussdh6fjjd67hkl7hff6feok4

30 July 2022

based on heuristic

mapped directly with Wikidata item

release_uussdh6fjjd67hkl7hff6feok4

1 reference

https://api.fatcat.wiki/v0/release/uussdh6fjjd67hkl7hff6feok4

30 July 2022

based on heuristic

mapped directly with Wikidata item

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

1 reference

https://api.fatcat.wiki/v0/release/uussdh6fjjd67hkl7hff6feok4

30 July 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

https://api.fatcat.wiki/v0/release/uussdh6fjjd67hkl7hff6feok4

30 July 2022

based on heuristic

mapped directly with Wikidata item

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28082855&oldid=1973929386"